Skip to main content
. 2022 Feb 17;3(4):100298. doi: 10.1016/j.jtocrr.2022.100298

Table 2.

Distribution of NSCLC-SAQ Items, Domains, and Total Score at Baseline

Items, Domains, Total Score Response Category, n (%)
Mean (SD) Median (Q1–Q3) Minimum–maximum
0, n (%) 1, n (%) 2, n (%) 3, n (%) 4, n (%)
Item 1. Cough 117 (21.8) 210 (39.2) 142 (26.5) 49 (9.1) 18 (3.4) 1.33 (1.02) 1.00 (1.00–2.00)
Item 2. Pain in chest 255 (47.6) 147 (27.4) 97 (18.1) 27 (5.0) 10 (1.9) 0.86 (1.00) 1.00 (0.00–1.50)
Item 3. Pain in areas other than chest 210 (39.2) 155 (28.9) 103 (19.2) 51 (9.5) 17 (3.2) 1.09 (1.12) 1.00 (0.00–2.00)
Item 4. Shortness of breath 159 (29.7) 146 (27.2) 129 (24.1) 77 (14.4) 25 (4.7) 1.37 (1.18) 1.00 (0.00–2.00)
Item 5. Lack of energy 113 (21.1) 143 (26.7) 158 (29.5) 95 (17.7) 27 (5.0) 1.59 (1.15) 2.00 (1.00–2.00)
Item 6. Tire easily 98 (18.3) 147 (27.4) 154 (28.7) 111 (20.7) 26 (4.9) 1.66 (1.14) 2.00 (1.00–3.00)
Item 7. Poor appetite 237 (44.2) 99 (18.5) 100 (18.7) 63 (11.8) 37 (6.9) 1.19 (1.30) 1.00 (0.00–2.00)
Derived pain domaina 1.36 (1.11) 1.00 (0.00–2.00) 0.00–4.00
Derived fatigue domaina 1.63 (1.09) 1.50 (1.00–2.50) 0.00–4.00
Total scoreb 6.88 (3.99) 6.75 (3.50–9.50) 0.00–18.00

Note: N equals 536 (response options for items 1 to 3: 0 = not at all; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe; response options for items 4 to 7: 0 = never; 1 = rarely; 2 = sometimes; 3 = often; 4 = always).

NSCLC-SAQ, NSCLC Symptom Assessment Questionnaire; Q1, first quartile; Q3, third quartile.

a

Derived domains are presented for comprehensiveness and are not intended to be used as an endpoint measure in clinical trials.

b

Total score ranges from 0 to 20 with higher scores indicating more severe NSCLC-related symptomatology.